The neu-oncogene product in serum and tissue of patients with breast carcinoma

Kath, R.; Höftken, K.; Otte, C.; Metz, K.; Scheulen, M. E.; Hülskamp, F.; Seeber, S.

doi:10.1093/oxfordjournals.annonc.a058593

Cited by 31 publications

(9 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since 1989, many reports have been published demonstrating the importance of quantifying the HER-2/neu ECD in serum or plasma of women with metastatic breast cancer (19)(20)(21)(22)(23)(24). Many of these studies have shown that breast cancer patients with elevated levels of serum HER-2/neu have a poor prognosis and shorter overall survival.…”

Section: Discussionmentioning

confidence: 99%

ADVIA Centaur^® Her-2/Neu Shows Value in Monitoring Patients with Metastatic Breast Cancer

et al. 2004

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

ADVIA Centaur^® Her-2/Neu Shows Value in Monitoring Patients with Metastatic Breast Cancer

et al. 2004

View full text Add to dashboard Cite

“…[24] have shown a poor response to tamoxifen therapy in patients with recurrent breast cancer and overexpression of the urokinase-type plasminogen activator and its inhibitor PAI-1. The amplification of the HER-2/neu oncogene leading to c-erbB2 protein overexpression and increased serum levels was implicated in several studies with early tumor recurrence, poor prognosis [2][3][4][13][14][15][16][17] and unfavorable response to first-line endocrine therapy [18,19] in breast cancer patients.…”

Section: Discussionmentioning

confidence: 99%

“…Determination of serum levels of shed c-erbB-2 oncoprotein in breast cancer patients showed increased soluble erbB-2 levels in patients with advanced breast cancer [13][14][15][16][17] associated with reduced response to adjuvant or neoadjuvant hormone or chemotherapy [18,19]. In patients with metastatic disease, elevated serum erbB-2 levels or erbB-2 overexpression in the tumor were associated with decreased response to firstline hormone or chemotherapy [20] or second-line hormone therapy [21].…”

Section: Introductionmentioning

confidence: 99%

Clinical Relevance of Soluble c-erbB-2 for Patients with Metastatic Breast Cancer Predicting the Response to Second-Line Hormone or Chemotherapy

Classen¹,

Kopp²,

Possinger³

et al. 2002

Tumor Biol

View full text Add to dashboard Cite

Concentrations of soluble c-erbB-2 were determined in the sera of 64 patients with distant metastasis from advanced breast cancer receiving second-line hormone or chemotherapy in comparison to 35 breast cancer patients without detectable recurrent disease and 17 healthy blood donors. The sera of non-metastatic breast cancer patients contained s-erbB-2 concentrations similar to those of healthy blood donors. Patients with distant metastasis from advanced breast cancer had significantly higher values of s-erbB-2 in comparison to patients with non-disseminated disease (mean: 59.6 vs. 11.6 U/ml; p = 0.022). A significant correlation was observed between s-erbB-2 serum levels and serum LDH concentrations (p < 0.001), levels of alkaline phosphatase (p < 0.001), and the presence of hepatic metastasis (p = 0.001). Time to tumor progression was significantly shorter in patients with s-erbB-2 levels above 40 U/ml (mean: 23.4 vs. 56.7 months; p = 0.002). Furthermore, breast cancer patients with hepatic metastasis and those with elevated s-erbB-2 serum levels above 40 U/ml had limited response to hormone or chemotherapy. Non-responders had significantly higher s-erbB-2 levels (mean: 270.3, range: 42–500 U/ml;) compared with the responder group (mean: 23.1, range: 0–149 U/ml; p < 0.001). Logistic regression analysis indicated that elevated s-erbB-2 serum levels above 40 U/ml independently predicted an unfavorable response to second-line hormone or chemotherapy in patients with advanced metastatic breast cancer.

show abstract

“…[27][28][29][30] Presently, there is no 'best method' to test for HER-2 overexpression. Although immunohistochemistry and FISH are the most often used clinical methods of testing, the requirement for primary and/or metastatic tumor tissue can be a disadvantage.…”

Section: Discussionmentioning

confidence: 99%

HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support

Bewick

Conlon

Gerard

et al. 2001

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:The expression levels of a circulating extracellular domain of HER-2 can be detected in the plasma and serum of patients with metastatic breast cancer using an enzyme immunoassay (ELISA) method. In this study, we evaluated the clinical significance of high and low levels of HER-2 in the plasma of 46 patients with metastatic breast cancer enrolled in a clinical trial of high-dose chemotherapy (HDCT) using cyclophosphamide, mitoxantrone, and paclitaxel with autologous stem cell transplantation (ASCT). Using 2500 U/ml as the cut-point, 20 patients (46%) had elevated HER-2 levels (HER-2 positive). Our results suggest that patients with metastatic breast cancer and high soluble plasma HER-2 have a significantly poorer overall (OS) and progression-free survival (PFS) following high-dose chemotherapy with paclitaxel and ASCT. The median OS of patients with low levels of HER-2 was significantly longer (P Ͻ 0.01) than the median OS of patients with high levels of HER-2 (29.8 months vs 15.9 months). PFS was also significantly longer (P Ͻ 0.01) for patients who were HER-2-negative, than for patients who were HER-2-positive (13.0 vs 8.6 months). Univariate analysis showed that patients with liver or lung metastases had significantly reduced OS and PFS. Patients with metastases to two or more sites also had a significantly reduced time to disease progression, but not OS. In multivariable analysis, lung metastases contributed along with HER-2-positive status to determine a group of patients with significantly poorer OS. However, HER-2-positive status remained the only independent predictor of PFS. Bone Marrow Transplantation (2001) 27, 847-853.

show abstract

The neu-oncogene product in serum and tissue of patients with breast carcinoma

Cited by 31 publications

References 22 publications

ADVIA Centaur^® Her-2/Neu Shows Value in Monitoring Patients with Metastatic Breast Cancer

ADVIA Centaur^® Her-2/Neu Shows Value in Monitoring Patients with Metastatic Breast Cancer

Clinical Relevance of Soluble c-erbB-2 for Patients with Metastatic Breast Cancer Predicting the Response to Second-Line Hormone or Chemotherapy

HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support

Contact Info

Product

Resources

About

The neu-oncogene product in serum and tissue of patients with breast carcinoma

Cited by 31 publications

References 22 publications

ADVIA Centaur® Her-2/Neu Shows Value in Monitoring Patients with Metastatic Breast Cancer

ADVIA Centaur® Her-2/Neu Shows Value in Monitoring Patients with Metastatic Breast Cancer

Clinical Relevance of Soluble c-erbB-2 for Patients with Metastatic Breast Cancer Predicting the Response to Second-Line Hormone or Chemotherapy

HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support

Contact Info

Product

Resources

About

ADVIA Centaur^® Her-2/Neu Shows Value in Monitoring Patients with Metastatic Breast Cancer

ADVIA Centaur^® Her-2/Neu Shows Value in Monitoring Patients with Metastatic Breast Cancer